Sarpogrelate hydrochloride is a selective SR-2A antagonist (pKi values are 8.52, 7.43 and 6.57 for SR-2A, SR-2C and SR-2B, respectively). Sarpogrelate hydrochloride has been shown to display selectivity over SR-1, SR-3, SR-4 H1, H2, M3, α1-adrenergic, α2-adrenergic and β-adrenergic receptors. It also displays cardioprotective activity in vivo.